Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?
The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu-DOTATATE. However, many aspects are still under discussion. In this 2-part article, we aim to collect and discuss current evidence...
Main Authors: | Wenjia Zhu, Meixi Liu, Li Huo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2023-12-01
|
Series: | Journal of Pancreatology |
Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000122 |
Similar Items
-
Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases
by: Rejoice Ngongoni, et al.
Published: (2022-10-01) -
Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
by: Deborah Theiler, et al.
Published: (2021-12-01) -
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
by: Maija Radzina, et al.
Published: (2023-10-01) -
Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
by: Sho Hasegawa, et al.
Published: (2022-07-01) -
The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
by: Virginia Liberini, et al.
Published: (2020-12-01)